CDA-AMC
Canada’s Drug Agency · L’Agence des médicaments du CanadaFormerly CADTH · Anciennement l’ACMTS
Veltarix (NSCLC) — Reimbursement Review
Jurisdictional note: Recommendations from CDA-AMC apply to all federal, provincial, and territorial drug plans except Quebec.
Recommendation type
Once final, the Reimbursement Review committee issues one of three recommendation types:
✓
Reimburse
Unconditional
!
Reimburse with conditions
Expected outcome (in progress)
✕
Do not reimburse
Per evidence + price gap
Review timeline · 205 days
1
Pre-submission
2
Filing review
3
Clinical review
4
pharmacoeconomic review
5
Patient/clinician input
6
Recommendation
Currently in stage 4 — Pharmacoeconomic review. 93 days to final recommendation.
Patient Input
3 patient group submissions received
- · Lung Cancer Canada
- · Canadian Cancer Society
- · Patient Group Coalition
Clinician Input
2 clinician group submissions received
- · Lung Cancer Disease Site Group
- · CAMO (Canadian Association of Medical Oncologists)
Canada’s Drug Agency (CDA-AMC) · 600-865 Carling Avenue, Ottawa ON · Demo mock